Glutathione Changes During Adriamycin Treatment in Ovarian Cancer
Author Information
Author(s): F.Y.F. Lee, D.W. Siemann, R.M. Sutherland
Primary Institution: University of Rochester Cancer Center
Hypothesis
The study investigates the role of glutathione in determining the sensitivity of ovarian cancer cells to adriamycin treatment.
Conclusion
Changes in cellular glutathione concentration during treatment may indicate how well tumor cells respond to adriamycin.
Supporting Evidence
- Cell lines showed inherent differences in sensitivity to adriamycin by a dose factor of up to 3.
- Resistance was closely correlated with positive changes in absolute GSH AUC following ADR treatment (r=0.92).
- Sensitive cell lines did not maintain high GSH levels during drug exposure.
Takeaway
This study found that ovarian cancer cells that can keep their glutathione levels high during treatment with adriamycin are more likely to survive.
Methodology
The study used human ovarian cancer cell lines to measure glutathione levels and their correlation with sensitivity to adriamycin treatment.
Limitations
The study did not explore all potential mechanisms of drug resistance beyond glutathione levels.
Participant Demographics
Cell lines were established from patients with diverse treatment histories.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website